JPWO2020173897A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020173897A5 JPWO2020173897A5 JP2021549919A JP2021549919A JPWO2020173897A5 JP WO2020173897 A5 JPWO2020173897 A5 JP WO2020173897A5 JP 2021549919 A JP2021549919 A JP 2021549919A JP 2021549919 A JP2021549919 A JP 2021549919A JP WO2020173897 A5 JPWO2020173897 A5 JP WO2020173897A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- fusion protein
- gpc3
- amino acid
- subunit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19000100.8 | 2019-02-26 | ||
| EP19000100 | 2019-02-26 | ||
| PCT/EP2020/054821 WO2020173897A1 (en) | 2019-02-26 | 2020-02-25 | Novel fusion proteins specific for cd137 and gpc3 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022523524A JP2022523524A (ja) | 2022-04-25 |
| JP2022523524A5 JP2022523524A5 (https=) | 2022-12-13 |
| JPWO2020173897A5 true JPWO2020173897A5 (https=) | 2022-12-13 |
| JP7476219B2 JP7476219B2 (ja) | 2024-04-30 |
Family
ID=65685094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021549919A Active JP7476219B2 (ja) | 2019-02-26 | 2020-02-25 | Ｃｄ１３７およびｇｐｃ３に特異的な新規融合タンパク質 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12486330B2 (https=) |
| EP (1) | EP3931209A1 (https=) |
| JP (1) | JP7476219B2 (https=) |
| KR (1) | KR20210133254A (https=) |
| CN (1) | CN113474359B (https=) |
| AU (1) | AU2020229436B2 (https=) |
| BR (1) | BR112021016829A2 (https=) |
| CA (1) | CA3124441A1 (https=) |
| IL (1) | IL284687B2 (https=) |
| MA (1) | MA55069A (https=) |
| MX (1) | MX2021010039A (https=) |
| SG (1) | SG11202106353VA (https=) |
| WO (1) | WO2020173897A1 (https=) |
| ZA (1) | ZA202104287B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020253034A1 (en) * | 2019-03-29 | 2021-08-19 | Pieris Pharmaceuticals Gmbh | Inhaled administration of lipocalin muteins |
| JP2024513264A (ja) * | 2021-04-05 | 2024-03-22 | サイトヴィア セラピューティクス， エルエルシー | Ｎｋｐ４６及びｇｐｃ３を標的とする二重特異性抗体、並びにその使用方法 |
| CA3216342A1 (en) * | 2021-04-23 | 2022-10-27 | Hassan ISSAFRAS | Anti-gpc3 antibodies, multispecific antibodies and methods of use |
| JP2024522078A (ja) * | 2021-05-21 | 2024-06-11 | ベイジーン スウィッツァーランド ゲーエムベーハー | 抗ｇｐｃ３及び抗ｃｄ１３７多重特異性抗体ならびにそれらの使用方法 |
| CA3228064A1 (en) * | 2021-08-12 | 2023-02-16 | Shanghai Jmt-Bio Technology Co., Ltd. | Gpc3-targeted antibody interferon .alpha. fusion protein and use thereof |
| WO2023036043A1 (zh) * | 2021-09-09 | 2023-03-16 | 广东东阳光药业有限公司 | 抗癌结合分子及其应用 |
| CN113956344A (zh) * | 2021-10-14 | 2022-01-21 | 江南大学 | 一种新型治疗肝癌的fgf类似物及其应用 |
| CN113912699A (zh) * | 2021-10-14 | 2022-01-11 | 江南大学 | 一种新型治疗乳腺癌的fgf类似物及其应用 |
| CN116640224A (zh) * | 2022-02-16 | 2023-08-25 | 北京免疫方舟医药科技有限公司 | Cd137抗体和cd40l的融合蛋白及其应用 |
| WO2023174401A1 (zh) * | 2022-03-18 | 2023-09-21 | 映恩生物制药（苏州）有限公司 | Gpc3抗体药物偶联物及其用途 |
| WO2023180523A1 (en) | 2022-03-24 | 2023-09-28 | Pieris Pharmaceuticals Gmbh | Process for purifying fusion proteins |
| CN119613552B (zh) * | 2024-07-23 | 2025-11-28 | 艾可泰科(浙江)控股有限公司 | 一组抗人gpc3纳米抗体突变体及嵌合抗原受体和应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DE69232137T2 (de) | 1991-11-25 | 2002-05-29 | Enzon Inc | Multivalente antigen-bindende proteine |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| US6080560A (en) | 1994-07-25 | 2000-06-27 | Monsanto Company | Method for producing antibodies in plant cells |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| CZ298681B6 (cs) | 1998-06-08 | 2007-12-19 | F. Hoffmann-La Roche Ag | Lécivo pro lécení infekcí chronické hepatitis C |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| US7211395B2 (en) | 2001-03-09 | 2007-05-01 | Dyax Corp. | Serum albumin binding moieties |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| WO2006056464A2 (en) | 2004-11-26 | 2006-06-01 | Pieris Ag | Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4) |
| EP1929073A4 (en) | 2005-09-27 | 2010-03-10 | Amunix Inc | PROTEIN MEDICAMENT AND ITS USE |
| WO2007107563A2 (en) | 2006-03-20 | 2007-09-27 | Technische Universität München | Muteins of tear lipocalin with affinity for the t-cell coreceptor cd4 |
| US8313924B2 (en) | 2006-08-01 | 2012-11-20 | Pieris Ag | Muteins of tear lipocalin and methods for obtaining the same |
| KR20150126724A (ko) * | 2007-09-28 | 2015-11-12 | 추가이 세이야쿠 가부시키가이샤 | 혈장 중 반응속도가 개선된 항-글리피칸-3 항체 |
| PT2614082T (pt) | 2010-09-09 | 2018-12-03 | Pfizer | Moléculas de ligação a 4-1bb |
| WO2013174783A1 (en) | 2012-05-23 | 2013-11-28 | Pieris Ag | Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3 |
| WO2014066328A1 (en) * | 2012-10-23 | 2014-05-01 | Oncomed Pharmaceuticals, Inc. | Methods of treating neuroendocrine tumors using wnt pathway-binding agents |
| MA40764A (fr) * | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| KR102734408B1 (ko) | 2015-05-04 | 2024-11-27 | 피어이스 파마슈티컬즈 게엠베하 | Cd137에 특이적인 신규한 단백질 |
| KR20170138574A (ko) | 2015-05-04 | 2017-12-15 | 피어이스 파마슈티컬즈 게엠베하 | 항암 융합 폴리펩타이드 |
| MX390894B (es) | 2015-05-18 | 2025-03-21 | Pieris Pharmaceuticals Gmbh | Polipéptido de fusión anti-cáncer. |
| AU2016262838B2 (en) | 2015-05-18 | 2020-10-08 | Pieris Pharmaceuticals Gmbh | Muteins of human lipocalin 2 with affinity for Glypican-3 (GPC3) |
| WO2018087108A1 (en) * | 2016-11-09 | 2018-05-17 | Pieris Pharmaceuticals Gmbh | Proteins specific for cd137 |
| RU2019124709A (ru) * | 2017-01-06 | 2021-02-08 | Момента Фармасьютикалз, Инк. | КОМПОЗИЦИИ И СПОСОБЫ, СВЯЗАННЫЕ СО СКОНСТРУИРОВАННЫМИ КОНСТРУКЦИЯМИ НА ОСНОВЕ Fc-АНТИГЕНСВЯЗЫВАЮЩЕГО ДОМЕНА |
| EP3638700B8 (en) * | 2017-06-14 | 2024-09-04 | Shihuida Pharmaceutical Group (Jilin) Co., Ltd., a China corporation | Proteinaceous heterodimer and use thereof |
-
2020
- 2020-02-25 MX MX2021010039A patent/MX2021010039A/es unknown
- 2020-02-25 US US17/433,155 patent/US12486330B2/en active Active
- 2020-02-25 CN CN202080016379.9A patent/CN113474359B/zh active Active
- 2020-02-25 KR KR1020217030737A patent/KR20210133254A/ko active Pending
- 2020-02-25 MA MA055069A patent/MA55069A/fr unknown
- 2020-02-25 SG SG11202106353VA patent/SG11202106353VA/en unknown
- 2020-02-25 WO PCT/EP2020/054821 patent/WO2020173897A1/en not_active Ceased
- 2020-02-25 AU AU2020229436A patent/AU2020229436B2/en active Active
- 2020-02-25 JP JP2021549919A patent/JP7476219B2/ja active Active
- 2020-02-25 CA CA3124441A patent/CA3124441A1/en active Pending
- 2020-02-25 BR BR112021016829-0A patent/BR112021016829A2/pt unknown
- 2020-02-25 IL IL284687A patent/IL284687B2/en unknown
- 2020-02-25 EP EP20705382.8A patent/EP3931209A1/en active Pending
-
2021
- 2021-06-22 ZA ZA2021/04287A patent/ZA202104287B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7827324B2 (ja) | インターロイキン－２バリアントおよびその使用方法 | |
| JP7850417B2 (ja) | 新規インターロイキン－２バリアントおよびその二官能性融合分子 | |
| US11505595B2 (en) | TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains | |
| JP7366056B2 (ja) | ＩＬ－１５／ＩＬ－１５ＲＡ Ｆｃ融合タンパク質およびＬＡＧ－３抗原結合ドメインを含む、ＬＡＧ－３を標的とするヘテロ二量体融合タンパク質 | |
| EP3180361B1 (en) | Recombinant antibody molecule and its use for target cell restricted t cell activation | |
| CN116063545B (zh) | 结合生长抑素受体2的异源二聚抗体 | |
| DK2536764T3 (en) | ANTI-CD28 HUMANIZED ANTIBODIES | |
| CN102665759B (zh) | 人源化抗il-22ra抗体 | |
| JP2021533203A5 (https=) | ||
| JP2007505643A5 (https=) | ||
| IL263211B2 (en) | Compositions and methods relating to engineered fc constructs | |
| JP2018519803A5 (https=) | ||
| US20220227867A1 (en) | ICOS TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND ICOS ANTIGEN BINDING DOMAINS | |
| JPWO2020173897A5 (https=) | ||
| CN113943370A (zh) | 抗pd-1/抗her2天然抗体结构的异源二聚双特异性抗体及其制备方法 | |
| CA3193273A1 (en) | Methods and compositions to treat autoimmune diseases and cancer | |
| CN108948207A (zh) | 一种人白细胞介素10-Fc融合蛋白及其编码基因与应用 | |
| KR20140135766A (ko) | 종양괴사인자 수용체 융합 단백질 및 이를 이용하는 방법 | |
| EP3850010A1 (en) | Improved anti-flt3 antigen binding proteins | |
| JPWO2020025659A5 (https=) | ||
| JP2016505277A (ja) | 組換え酵母形質転換体及びこれを用いた免疫グロブリンＦｃ断片の生産方法 | |
| JP2024539749A (ja) | 新規な抗体－サイトカイン融合タンパク質及びその製造方法と使用 | |
| EP3623383A1 (en) | Improved bispecific flt3xcd3 antigen binding proteins | |
| CN115551538A (zh) | 干扰IL-1β受体信号转导的药剂 | |
| RU2815388C2 (ru) | Многофункциональные слитые белки и их применения |